A Phase I Study of Lenalidomide Plus Pembrolizumab in Patients With Relapsed and/or Refractory Solid Tumors With Phase II Expansion in Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2018 Status changed from recruiting to discontinued as per recommendation of PI.
- 05 Apr 2017 Status changed from not yet recruiting to recruiting.
- 25 Jan 2017 Planned initiation date changed from 1 Nov 2016 to 1 Feb 2017.